Bevacizumab in Treating Patients With Myelodysplastic Syndrome

Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PURPOSE: This phase I/II trial is to see if bevacizumab works in treating patients who have myelodysplastic syndrome.

Timeline

Start

2001-08

Primary completion

—

Completion

2004-11

Drugs

Indications